[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1757
1. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Mediastinum / pathology. Medical Oncology / methods. Middle Aged. Prognosis. Remission Induction. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


2. Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, Xu W, Li J: JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma; 2008 Apr;49(4):696-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 99 Chinese myeloproliferative disorder patients and 120 additional patients with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes were studied.
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Genetic Testing. Hematocrit. Hemoglobins / analysis. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Myelodysplastic Syndromes / genetics. Myeloproliferative Disorders / genetics. Neutrophils / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398736.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


3. Pulte D, Gondos A, Brenner H: Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer; 2009 Nov 1;115(21):4973-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: : Period analysis was used to calculate 5- and 10-year relative survival for adolescents and young adults diagnosed with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), and chronic myelocytic leukemia (CML) for 5 5-year periods from 1981-1985 to 2001-2005, using data from the Surveillance, Epidemiology, and End Results database.
  • Increases in 10-year relative survival between 1981-1985 and 2001-2005 were as follows: HL, from 80.4% to 93.4%; NHL, from 55.6% to 76.2%; ALL, from 30.5% to 52.1%; AML, from 15.2% to 45.1%; CML, from 0 to 74.5% (P < .001 in all cases).
  • [MeSH-minor] Adolescent. Hodgkin Disease / mortality. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality. Leukemia, Myeloid, Acute / mortality. Lymphoma, Non-Hodgkin / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Survival Rate. Time Factors. United States / epidemiology. Young Adult

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705347.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Paulsson K, Horvat A, Fioretos T, Mitelman F, Johansson B: Formation of der(19)t(1;19)(q23;p13) in acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2005 Feb;42(2):144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formation of der(19)t(1;19)(q23;p13) in acute lymphoblastic leukemia.
  • The t(1;19)(q23;p13), which results in a fusion of TCF3 (previously E2A) at 19p13 with PBX1 at 1q23, is one of the most common translocations in acute lymphoblastic leukemia (ALL).
  • At least two other mechanisms are possible for the formation of the der(19): an initial trisomy 1 followed by translocation and subsequent loss of the der(1) or a rearrangement during the G2 phase of the cell cycle, with the derivative chromosomes 1 and 19 ending up in separate daughter cells.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Cytogenetic Analysis. Female. Homeodomain Proteins / genetics. Humans. Male. Middle Aged. Oncogene Proteins, Fusion / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15543624.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


5. Akay OM, Urer SM, Oner U, Gulbas Z: Lipomembranous panniculitis in a patient with acute leukemia induced by chemotherapy. Leuk Res; 2008 Apr;32(4):669-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adipose Tissue / drug effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Panniculitis / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Fat Necrosis / chemically induced. Female. Humans. Methotrexate / administration & dosage

  • Genetic Alliance. consumer health - Panniculitis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915316.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Miyoshi I, Kubota T, Taguchi H: Beau's lines after chemotherapy for ALL. Intern Med; 2007;46(1):61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nails / drug effects. Nails / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Asparaginase / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202738.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


7. Dictor M, Warenholt J, György C, Månsson I, Larsson G: Clonal evolution to histiocytic sarcoma with the BCR/ABL rearrangement 14 years after acute lymphoblastic leukemia. Leuk Lymphoma; 2009 Nov;50(11):1892-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution to histiocytic sarcoma with the BCR/ABL rearrangement 14 years after acute lymphoblastic leukemia.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Histiocytic Sarcoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Base Sequence. Clone Cells / metabolism. Clone Cells / pathology. Female. Humans. Immunoglobulin Variable Region / genetics. In Situ Hybridization, Fluorescence. Molecular Sequence Data

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883318.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


8. Patistea E: Description and adequacy of parental coping behaviours in childhood leukaemia. Int J Nurs Stud; 2005 Mar;42(3):283-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adaptation, Psychological. Attitude to Health. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Child. Child, Preschool. Communication. Family Health. Fear. Female. Greece. Hospitals, Pediatric. Humans. Life Change Events. Male. Middle Aged. Nursing Methodology Research. Professional-Family Relations. Self Concept. Sex Factors. Social Support. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708015.001).
  • [ISSN] 0020-7489
  • [Journal-full-title] International journal of nursing studies
  • [ISO-abbreviation] Int J Nurs Stud
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, Wattel MM, van Esser JW, Valk PJ, Cornelissen JJ: Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia; 2009 Mar;23(3):627-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Neoplasm Proteins / antagonists & inhibitors. Oncogene Proteins, Fusion / antagonists & inhibitors. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Dasatinib. Daunorubicin / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. In Situ Hybridization, Fluorescence. Male. Methotrexate / administration & dosage. Mitoxantrone / administration & dosage. Neutropenia / chemically induced. Neutropenia / drug therapy. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Remission Induction. Splenic Rupture / etiology. Splenic Rupture / surgery. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987655.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NUP214-ABL1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Pyrimidines; 0 / Thiazoles; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; BZ114NVM5P / Mitoxantrone; EC 3.5.1.1 / Asparaginase; RBZ1571X5H / Dasatinib; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL: EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood; 2006 Feb 1;107(3):898-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.
  • The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthesis.
  • We demonstrate that MTAP- T-ALL cells obtained at relapse are as sensitive to L-alanosine toxicity as diagnosis samples.
  • The therapeutic index of L-alanosine can be increased by the use of a MTAP substrate, which protects MTAP+ normal cells.
  • In addition, EFA selectively rescued MTAP+ MOLT-4 cells from L-alanosine toxicity at 25 microM with negligible toxicity even at 100 microM.
  • EFA at 20 microM or less rescued primary MTAP+ T-ALL cells and normal lymphocytes from L-alanosine toxicity.
  • Collectively, these data indicate that EFA is an effective agent for salvaging MTAP+ cells from L-alanosine toxicity and is superior to MTA due to lower cytotoxicity.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 1989 Sep;53(3):800-6 [2547901.001]
  • [Cites] Blood. 1989 Mar;73(4):952-60 [2920215.001]
  • [Cites] Mol Cell Biol. 1992 Jan;12(1):103-11 [1729592.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1098-101 [8382555.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2410-5 [7683574.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3396-7 [8012957.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]
  • [Cites] J Med Chem. 1995 Mar 31;38(7):1174-88 [7707320.001]
  • [Cites] Blood. 1995 May 1;85(9):2321-30 [7727766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6489-93 [7604019.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6203-8 [8650244.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3083-90 [8874207.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5653-8 [8971171.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2602-5 [9205063.001]
  • [Cites] Clin Cancer Res. 1997 Mar;3(3):433-8 [9815702.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1492-7 [10197619.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):683-90 [12875987.001]
  • [Cites] Biochem Pharmacol. 2003 Aug 15;66(4):613-21 [12906926.001]
  • [Cites] Oncol Res. 2004;14(7-8):373-9 [15301428.001]
  • [Cites] J Pharm Sci. 1967 Jul;56(7):865-70 [4962273.001]
  • [Cites] Biochem Pharmacol. 1968 Mar;17(3):363-8 [5690813.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Biochem Biophys Res Commun. 1978 Jul 14;83(1):27-35 [100109.001]
  • [Cites] Biochem Pharmacol. 1978;27(17):2163-9 [310308.001]
  • [Cites] Circ Res. 1979 Oct;45(4):468-78 [476869.001]
  • [Cites] Biochem Pharmacol. 1980 Feb;29(2):227-45 [7362636.001]
  • [Cites] Can J Physiol Pharmacol. 1980 Jun;58(6):673-91 [6253037.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4390-7 [7438071.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1533-5 [7007366.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):1219-23 [6785752.001]
  • [Cites] Blood. 1982 Dec;60(6):1387-91 [6814551.001]
  • [Cites] Clin Chim Acta. 1983 Mar 14;128(2-3):283-90 [6406103.001]
  • [Cites] Adv Pharmacol Chemother. 1984;20:69-121 [6398969.001]
  • [Cites] Mutat Res. 1986 Jun;161(1):1-7 [3517630.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5409-12 [3093064.001]
  • [Cites] Breast Cancer Res Treat. 1987;9(1):53-9 [3109530.001]
  • [Cites] Blood. 1988 Jun;71(6):1568-73 [3130904.001]
  • [Cites] Biochem Pharmacol. 1988 May 15;37(10):2085-9 [3377811.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3193-7 [1904005.001]
  • (PMID = 16234352.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00827
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 9-beta-D-erythrofuranosyladenine; 0 / Antibiotics, Antineoplastic; 0 / Deoxyadenosines; 0 / Enzyme Inhibitors; 0 / Furans; 0 / Thionucleosides; 2CNI71214Y / alanosine; 634Z2VK3UQ / 5'-methylthioadenosine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase; JAC85A2161 / Adenine; OF5P57N2ZX / Alanine
  • [Other-IDs] NLM/ PMC1895892
  •  go-up   go-down


11. Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA: Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia. J Mol Diagn; 2009 May;11(3):194-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
  • Molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia were identified by determining, at the time of diagnosis, the repertoire of rearrangements of the immunoglobulin heavy chain (IGH) gene using segment-specific variable (V), diversity (D), and junctional (J) primers in two different studies that involved a total study population of 75 children and 18 adults.
  • IGH repertoire analysis at diagnosis has potential advantages for the identification of molecular markers for the quantification of minimal residual disease in acute lymphoblastic leukemia cases.
  • [MeSH-major] Cell Lineage. Gene Rearrangement, B-Lymphocyte. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Child. Cooperative Behavior. DNA, Neoplasm / genetics. Genetic Markers. Genome, Human / genetics. Humans. Neoplasm, Residual / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Aug;14(8):1426-35 [10942239.001]
  • [Cites] J Mol Diagn. 2009 May;11(3):201-10 [19324989.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):71-90 [11987917.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4520-6 [12946997.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W435-40 [15215425.001]
  • [Cites] Blood. 1987 Oct;70(4):1079-83 [3477297.001]
  • [Cites] Leukemia. 1990 Nov;4(11):727-31 [2172664.001]
  • [Cites] Blood. 1993 Jul 15;82(2):581-9 [8329713.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):196-200 [7904666.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1847-50 [7475273.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2192-9 [9447840.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):591-8 [9718378.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D593-7 [15608269.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):706-13 [17287857.001]
  • [Cites] Blood. 2007 Jul 15;110(2):632-9 [17371950.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1607-11 [17485550.001]
  • [Cites] Leukemia. 2008 Apr;22(4):771-82 [18239620.001]
  • [Cites] Leukemia. 2001 Jan;15(1):134-40 [11243381.001]
  • (PMID = 19324994.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / Immunoglobulin Heavy Chains
  • [Other-IDs] NLM/ PMC2671336
  •  go-up   go-down


12. Mahmoud LA, Shamaa SS, Salem MA, Aladle DA, Goda EF: A study for evaluation of different diagnostic approaches in acute leukemia in Egypt. Hematology; 2006 Apr;11(2):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Female. Genetic Markers. Histocytochemistry / methods. Humans. Immunophenotyping / methods. In Situ Hybridization, Fluorescence. Karyotyping. Male. Prognosis. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753847.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


13. Nakamura S, Okinaka K, Hirano I, Ono T, Sugimoto Y, Shigeno K, Fujisawa S, Shinjo K, Ohnishi K: KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. Leuk Res; 2008 Sep;32(9):1358-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells.
  • CEM, MOLT4 and SUP-B15 cells were transduced with lentivirus-mediated siRNA KIS gene.
  • On the other hand, the mRNA expressions of p27(Kip1) in CEM, MOLT4 and SUP-B15 cells were not affected by the transduction with siRNA KIS gene.
  • We showed that KIS protein directly interacted with p27(Kip1) protein, and reduction of KIS inhibited the S10 phosphorylation of p27(Kip1) in leukemia cells.
  • On these cells transfected with siRNA KIS, the inhibition of S10 phosphorylation of p27(Kip1) was strongly suppressed cell proliferation in a time-dependent manner.
  • We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
  • This study demonstrates that the elevated levels of KIS protein in leukemia cells promote the cell cycle progression in leukemia cells.
  • [MeSH-major] Cell Cycle / physiology. Cell Proliferation. Intracellular Signaling Peptides and Proteins / metabolism. Intracellular Signaling Peptides and Proteins / physiology. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Bone Marrow / metabolism. Bone Marrow / pathology. Cells, Cultured. Cyclin-Dependent Kinase Inhibitor p27. Humans. Immunoprecipitation. Leukocytes, Mononuclear / metabolism. Leukocytes, Mononuclear / pathology. Middle Aged. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384876.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / UHMK1 protein, human
  •  go-up   go-down


14. Withycombe JS, Post-White JE, Meza JL, Hawks RG, Smith LM, Sacks N, Seibel NL: Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer; 2009 Dec 15;53(7):1249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
  • BACKGROUND: This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.
  • PROCEDURE: Patients (1,638) were enrolled in CCG 1961 from November 1996 to May 2002.
  • Weight was measured as BMI percent (%), specific for age and gender, and defined as 100 x ln(BMI/median BMI).
  • RESULTS: By the end of treatment, 23% of children were obese (BMI >or=95%), compared with 14% at diagnosis.
  • Children who received post-induction intensified therapy (arms C, D, SER with Doxorubicin or Idarubicin) had higher gastrointestinal toxicities and lower BMI% from consolidation through interim maintenance 1.
  • BMI% then increased for all arms between delayed intensification and maintenance 1 or 2.
  • Children who were of Black or Hispanic race, obese at diagnosis, or who had grade 3 or 4 pancreatitis/glucose toxicities during induction had higher BMI% throughout treatment.
  • Children were more likely to be obese at the end of the study if they were aged 5-9 years at diagnosis or female gender.
  • Cranial radiation was not a predictor of obesity.
  • CONCLUSIONS: Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation.
  • The beginning of maintenance therapy may be the best time to intervene with nutritional and behavioral interventions, particularly for children who are obese or aged 5-9 years at diagnosis, female, Black or Hispanic, or those with metabolic toxicities during induction.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3742-5 [11502805.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):557-68 [12754700.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Pediatrics. 2003 Aug;112(2):424-30 [12897303.001]
  • [Cites] Arch Dis Child. 2003 Sep;88(9):748-52 [12937090.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1141-51 [14513062.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26 [15087948.001]
  • [Cites] Arch Dis Child. 1994 Aug;71(2):147-9 [7944537.001]
  • [Cites] J Pediatr. 1995 Jul;127(1):63-7 [7608813.001]
  • [Cites] Pediatr Res. 1995 Jul;38(1):86-90 [7478803.001]
  • [Cites] Stat Med. 1997 Aug 30;16(16):1859-71 [9280038.001]
  • [Cites] Int J Cancer Suppl. 1998;11:81-4 [9876486.001]
  • [Cites] Eur J Clin Nutr. 2005 Mar;59(3):419-25 [15674315.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1725-9 [15754333.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1730-9 [15761876.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] Am J Clin Nutr. 2006 Jan;83(1):70-4 [16400052.001]
  • [Cites] J Pediatr Oncol Nurs. 2006 May-Jun;23(3):135-42 [16624889.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] Psychooncology. 2007 May;16(5):448-57 [16915562.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2063-9 [17513811.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Apr-May;17(3):231-7 [10779989.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • (PMID = 19688832.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01; United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS144355; NLM/ PMC3044478
  •  go-up   go-down


15. Rubin CS, Holmes AK, Belson MG, Jones RL, Flanders WD, Kieszak SM, Osterloh J, Luber GE, Blount BC, Barr DB, Steinberg KK, Satten GA, McGeehin MA, Todd RL: Investigating childhood leukemia in Churchill County, Nevada. Environ Health Perspect; 2007 Jan;115(1):151-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Environmental Exposure / analysis. Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Environmental Pollutants / analysis. Female. Humans. Male. Metals / analysis. Nevada / epidemiology. Pesticides / analysis. Polychlorinated Biphenyls / analysis. Radiation, Ionizing. Risk Factors. Water Supply / analysis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):231-40 [10670547.001]
  • [Cites] Epidemiology. 1995 Nov;6(6):575-6 [8589086.001]
  • [Cites] Cancer Causes Control. 2000 Apr;11(4):303-7 [10843442.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2000 Nov-Dec;10(6 Pt 2):672-81 [11138659.001]
  • [Cites] Arch Environ Health. 2001 Mar-Apr;56(2):157-66 [11339680.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Int Arch Occup Environ Health. 1996;68(3):183-7 [8919847.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):3-16 [9045302.001]
  • [Cites] IARC Sci Publ. 1996;(135):1-20 [9103929.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Environ Health Perspect. 2005 Feb;113(2):192-200 [15687057.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):138-45 [17366834.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):158-64 [17366837.001]
  • [Cites] J Anal Toxicol. 2002 Jul-Aug;26(5):245-52 [12166810.001]
  • [Cites] Cancer Invest. 2002;20(5-6):810-6 [12206154.001]
  • [Cites] Anal Chem. 2004 May 1;76(9):2453-61 [15117183.001]
  • [Cites] Environ Health Perspect. 2004 May;112(6):766-71 [15121523.001]
  • [Cites] Arch Environ Contam Toxicol. 2004 Apr;46(3):281-8 [15195798.001]
  • [Cites] CA Cancer J Clin. 2004 Sep-Oct;54(5):273-80 [15371285.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]
  • [Cites] Public Health Rep. 2004 Nov-Dec;119(6):521-35 [15504444.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2420-3 [4230121.001]
  • [Cites] South Med J. 1976 Dec;69(12):1598-1602 [1019679.001]
  • [Cites] JAMA. 1988 May 13;259(18):2715-9 [2833632.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1):1-8 [2356803.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1 Suppl):S43-7 [2162625.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1 Suppl):S6-13 [2356837.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] Environ Health Perspect. 1990 Nov;89:145-51 [2088741.001]
  • [Cites] Sci Total Environ. 1992 Dec 15;127(1-2):173-85 [1480954.001]
  • [Cites] BMJ. 1993 Apr 3;306(6882):930 [8490436.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1339-49 [8519643.001]
  • [Cites] J Chromatogr Sci. 2000 Feb;38(2):49-54 [10677832.001]
  • (PMID = 17366836.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Metals; 0 / Pesticides; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ PMC1797848
  •  go-up   go-down


16. Steiner M, Attarbaschi A, König M, Gadner H, Haas OA, Mann G: Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child, Preschool. Chromosomes, Human, Pair 21 / genetics. Core Binding Factor Alpha 2 Subunit. Female. Humans. In Situ Hybridization, Fluorescence. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • (PMID = 15770827.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


17. Mandal S, Jain S, Khurana N: Breast lump as an initial manifestation in acute lymphoblastic leukemia: an unusual presentation. A case report. Hematology; 2007 Feb;12(1):45-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast lump as an initial manifestation in acute lymphoblastic leukemia: an unusual presentation. A case report.
  • Breast lump as a presenting manifestation of acute lymphoblastic lymphoma (ALL) leukemia is extremely rare.
  • [MeSH-major] Breast / pathology. Leukemic Infiltration / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Bone Marrow Examination. Breast Neoplasms / diagnosis. Diagnosis, Differential. Diagnostic Errors. Female. Fever / etiology. Fibroadenoma / diagnosis. Humans. Lymphoma, Non-Hodgkin / diagnosis. Weight Loss

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364992.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. D'Achille P, Seymour JF, Campbell LJ: Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet; 2006 Nov;171(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.
  • We present a series of 12 cases of de novo acute lymphoblastic leukemia (ALL) with translocation t(14;18)(q32;q21).
  • The median age of patients at presentation was 65.5 years, and no patient presented with a past history or any clinical evidence of lymphoma.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD19 / analysis. Antigens, CD20 / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neprilysin / analysis. Sialic Acid Binding Ig-like Lectin 2 / analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074591.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Sialic Acid Binding Ig-like Lectin 2; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 32
  •  go-up   go-down


19. Girod A, Breton P: [Two cases of malignant tumors of the face after hematopoietic stem cell transplantation]. Rev Stomatol Chir Maxillofac; 2005 Apr;106(2):107-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous cell carcinoma of the oral cavity after HSCT presents the same clinical, histological and prognostic features as in the non-grafted patient.
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / etiology. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924098.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Lo A, Gu G, Liu M, Dev VG: ABL deletion without associated BCR-ABL in precursor B-cell acute lymphoblastic leukemia. Leuk Res; 2009 Aug;33(8):e98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABL deletion without associated BCR-ABL in precursor B-cell acute lymphoblastic leukemia.
  • [MeSH-major] Gene Deletion. Genes, abl. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chromosome Aberrations. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282030.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


21. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ: Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood; 2009 Mar 26;113(13):2902-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation.
  • Twenty-two adult acute lymphoblastic leukemia (ALL) patients (21 of 22 in complete remission [CR]) received reduced-intensity conditioning followed by allogeneic transplantation.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Siblings. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Graft vs Host Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Recurrence. Survival Analysis. Tissue Donors. Transplantation, Homologous. Young Adult


22. Surapolchai P, Hongeng S, Mahachoklertwattana P, Pakakasama S, Winaichatsak A, Wisanuyothin N, Pasomsub E, Mahasirimongkol S, Sirachainan N: Impaired glucose tolerance and insulin resistance in survivors of childhood acute lymphoblastic leukemia: prevalence and risk factors. J Pediatr Hematol Oncol; 2010 Jul;32(5):383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired glucose tolerance and insulin resistance in survivors of childhood acute lymphoblastic leukemia: prevalence and risk factors.
  • AIM/PURPOSE: Survivors of acute lymphoblastic leukemia (ALL) are at increased risks of impaired glucose metabolism, insulin resistance, and metabolic syndrome.
  • [MeSH-major] Blood Glucose / metabolism. Glucose Tolerance Test. Insulin Resistance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. DNA, Neoplasm / genetics. Female. Homeodomain Proteins / genetics. Humans. Infant. Male. Paired Box Transcription Factors / genetics. Prevalence. Risk Factors. Sex Factors. Survival Rate. Survivors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485196.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / PAX4 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


23. Lee HY, Im SI, Kang MH, Kim KM, Kim SH, Kim HG, Kang JH, Lee GW: Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia. Yonsei Med J; 2008 Feb 29;49(1):151-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irreversible paraplegia following one time prophylactic intrathecal chemotherapy in an adult patient with acute lymphoblastic leukemia.
  • We present an adult female patient who developed irreversible paraplegia and areflexia four days post intrathecal chemotherapy with methotrexate, cytosine arabinoside and hydrocortisone.
  • On magnetic resonance imaging (MRI) of the lumbar spine, diffuse gadolinium enhancement of the anterior spinal nerve roots (ventral roots) was detected.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Paraplegia / chemically induced. Paraplegia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Paraplegia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mil Med. 2002 Feb;167(2):157-60 [11873541.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 May;27(5):270-2 [15891563.001]
  • [Cites] N Engl J Med. 1973 Oct 11;289(15):770-3 [4517004.001]
  • [Cites] J Pediatr. 1973 Dec;83(6):988-92 [4800714.001]
  • [Cites] Cancer. 1976 Apr;37(4):1663-8 [946593.001]
  • [Cites] Cancer. 1977 Dec;40(6):2817-22 [271037.001]
  • [Cites] Cancer. 1978 Sep;42(3):1211-5 [581272.001]
  • [Cites] Cancer. 1979 Jan;43(1):83-5 [282937.001]
  • [Cites] Acta Neuropathol. 1980;49(3):231-5 [6929156.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1724-37 [6793225.001]
  • [Cites] Cancer. 1982 Jul 1;50(1):42-7 [6177392.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1115-23 [6362838.001]
  • [Cites] Semin Oncol. 1985 Jun;12(2):131-48 [3892694.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1083-8 [3455842.001]
  • [Cites] Eur J Haematol. 1987 Jul;39(1):75-6 [3477471.001]
  • [Cites] Arch Phys Med Rehabil. 1988 Dec;69(12):1054-6 [3214264.001]
  • [Cites] Cancer Res. 1989 May 1;49(9):2502-5 [2468411.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):452-7 [2297635.001]
  • [Cites] Med Pediatr Oncol. 1990;18(2):159-61 [2304423.001]
  • [Cites] Med Pediatr Oncol. 1991;19(3):192-8 [2023567.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):117-23 [8416707.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3034-41 [7954266.001]
  • [Cites] Pediatr Neurol. 1999 Aug;21(2):576-8 [10465148.001]
  • [Cites] Cancer. 1972 Feb;29(2):370-4 [4552135.001]
  • (PMID = 18306482.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2615263
  •  go-up   go-down


24. Miyazaki Y: [Adult leukemia: current status of the clinical studies in Japan Adult Leukemia Study Group]. Rinsho Ketsueki; 2006 Jul;47(7):579-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult leukemia: current status of the clinical studies in Japan Adult Leukemia Study Group].
  • [MeSH-major] Clinical Trials as Topic / standards. Multicenter Studies as Topic / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Clinical Protocols. Financing, Government. Hematopoietic Stem Cell Transplantation. Humans. Medical Oncology / organization & administration. Middle Aged

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910566.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Dai L, Gast A, Horska A, Schrappe M, Bartram CR, Hemminki K, Kumar R, Bermejo JL: A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes. Pediatr Blood Cancer; 2009 Jul;52(7):819-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of childhood acute lymphoblastic leukaemia and polymorphisms in the TGF-beta and receptor genes.
  • BACKGROUND: Inherited genetic variants in critical genes can putatively modulate susceptibility to childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Polymorphism, Single Nucleotide / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / genetics
  • [MeSH-minor] Adult. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Case-Control Studies. Child. Female. Haplotypes / genetics. Humans. Male. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19229971.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


26. Yi DH, Rashid S, Cibas ES, Arrigg PG, Dana MR: Acute unilateral leukemic hypopyon in an adult with relapsing acute lymphoblastic leukemia. Am J Ophthalmol; 2005 Apr;139(4):719-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute unilateral leukemic hypopyon in an adult with relapsing acute lymphoblastic leukemia.
  • PURPOSE: To report acute unilateral hypopyon uveitis as an initial presenting feature of relapsing acute lymphoblastic leukemia (ALL) in an adult patient.
  • RESULTS: Examination of the aqueous humor aspirate revealed presence of malignant cells compatible with the previous bone marrow biopsy and subsequent spinal tap results.
  • [MeSH-major] Anterior Chamber / pathology. Eye Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Uveitis, Anterior / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aqueous Humor / cytology. Bone Marrow Cells / pathology. Cerebrospinal Fluid / cytology. Glaucoma / diagnosis. Humans. Intraocular Pressure. Leukemic Infiltration. Male. Middle Aged. Suppuration / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808176.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Davidsson J, Andersson A, Paulsson K, Heidenblad M, Isaksson M, Borg A, Heldrup J, Behrendtz M, Panagopoulos I, Fioretos T, Johansson B: Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet; 2007 Sep 15;16(18):2215-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3.
  • Although gain of 1q occurs in 25% of Burkitt lymphomas (BLs) and 10% of pediatric high hyperdiploid acute lymphoblastic leukemias (ALLs), little is known about the origin, molecular genetic characteristics and functional outcome of dup(1q) in these disorders.
  • The DAP3 protein has been reported to be highly expressed in invasive glioblastoma multiforme cells, whereas expression of the UCK2 protein has been correlated with sensitivity to anticancer drugs.
  • [MeSH-major] Burkitt Lymphoma / genetics. Centromere / genetics. Chromosomes, Human, Pair 1 / genetics. DNA Methylation. Gene Expression Regulation, Leukemic. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diploidy. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

  • Guide to Pharmacology. gene/protein/disease-specific - regulator of G-protein signaling 16 - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613536.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


28. Hashemzadeh S, Tubbs RS, Fakhree MB, Shoja MM: Mucormycotic pseudoaneurysm of the common carotid artery with tracheal involvement. Mycoses; 2008 Jul;51(4):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient with acute lymphoblastic leukaemia (L2 subtype) who developed a neck mass following a course of induction chemotherapy.
  • [MeSH-major] Aneurysm, False / microbiology. Carotid Artery, Common / microbiology. Mucormycosis / complications. Mucormycosis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Humans. Male. Mucorales / cytology. Tracheal Diseases / etiology. Tracheal Diseases / surgery

  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855846.001).
  • [ISSN] 1439-0507
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


29. Pais AP, Amare Kadam PS, Raje GC, Banavali S, Parikh P, Kurkure P, Arora B, Gujral S, Kumar SA, Badrinath Y: RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL. Pediatr Hematol Oncol; 2008 Sep;25(6):582-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A large-cohort study (619) of acute lymphoblastic leukemia (ALL) revealed an ETV6/RUNX1 (previously known as TEL/AML1) incidence of 18% in pediatric B-cell precussor ALL, indicating no geographical heterogeinity.
  • [MeSH-major] Chromosome Aberrations. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728978.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins
  •  go-up   go-down


30. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ: Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer; 2008 Oct 1;113(7 Suppl):1933-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%.
  • [MeSH-major] Leukemia / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


31. Morimoto A, Imamura T, Ishii R, Nakabayashi Y, Nakatani T, Sakagami J, Yamagami T: Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer; 2008 Sep 15;113(6):1362-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).
  • [MeSH-minor] Child. Child, Preschool. Drug Therapy, Combination. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18661511.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Protease Inhibitors; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


32. Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, Min WS, Kang CS, Kim WI, Shim SI, Han K: Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci; 2006;36(1):7-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia.
  • The quantitative levels of intracellular cytokines IL-4, IL-10, and IFN-gamma (ie, the number of bound PE-conjugated antibody molecules/cell) of leukemic cells and bone marrow T cells (bmT cells) of acute leukemia patients were analyzed by flow cytometry.
  • In bmT cells, the IL-10 level was highest in the dysplastic AML group (972 +/- 1049) and lowest in the APL group (397 +/- 352).
  • The cytokine levels of bmT cells at the time of CR became normal and were not different among the diagnosis groups.
  • In summary, leukemic cell and bmT cell cytoplasmic expression profiles of IL-4, IL-10, and IFN-gamma are characteristic for each diagnostic group of acute leukemia patients and the profiles of bmT cells are normal at the time of CR.
  • [MeSH-major] Bone Marrow Cells / metabolism. Interferon-gamma / blood. Interleukin-10 / blood. Interleukin-4 / blood. Leukemia / metabolism. T-Lymphocytes / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Remission Induction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501231.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


33. Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Loraine Karran E, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJ, Harrison CJ: t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood; 2008 Jan 01;111(1):387-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
  • Translocations involving the immunoglobulin heavy chain locus (IGH@) at chromosome band 14q32 are common in mature B-cell neoplasms, but are rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Inhibitor of Differentiation Proteins / genetics. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Child. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 9. Female. Gene Deletion. Genes, p16. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Molecular Sequence Data. PAX5 Transcription Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940204.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Inhibitor of Differentiation Proteins; 0 / PAX5 Transcription Factor; 0 / PAX5 protein, human
  •  go-up   go-down


34. Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A, Flohr T, Schäfer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M: Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood; 2005 Jan 15;105(2):821-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
  • Treatment resistance, as indicated by the presence of high levels of minimal residual disease (MRD) after induction therapy and induction consolidation, is associated with a poor prognosis in childhood acute lymphoblastic leukemia (ALL).
  • We hypothesized that treatment resistance is an intrinsic feature of ALL cells reflected in the gene expression pattern and that resistance to chemotherapy can be predicted before treatment.
  • We conclude that resistance to chemotherapy seems at least in part to be an intrinsic feature of ALL cells.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Gene Expression Profiling. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. B-Lymphocytes / physiology. Child. Child, Preschool. Cluster Analysis. Female. Gene Expression Regulation, Leukemic. Humans. Infant. Male. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Predictive Value of Tests. Prognosis


35. Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol; 2007 Aug 20;25(24):3739-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.
  • We hypothesized that like ERG, BAALC expression might be of prognostic significance in acute T-lymphoblastic leukemia (T-ALL) and that ERG and BAALC expression together would better identify the patient's risk profile.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Expression. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Organotechnetium Compounds. Oximes. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / DNA-Binding Proteins; 0 / ERG protein, human; 0 / Neoplasm Proteins; 0 / Organotechnetium Compounds; 0 / Oximes; 0 / Trans-Activators; 0 / technetium Tc 99m 4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime
  •  go-up   go-down


36. Gavhed D, Akefeldt SO, Osterlundh G, Laurencikas E, Hjorth L, Blennow K, Rosengren L, Henter JI: Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Pediatr Blood Cancer; 2009 Dec 15;53(7):1264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred ten children with newly diagnosed acute lymphoblastic leukemia (ALL) served as controls.
  • [MeSH-minor] Adolescent. Biomarkers. Brain / pathology. Brain / radiography. Child. Child, Preschool. Cognition Disorders / cerebrospinal fluid. Cognition Disorders / etiology. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Male. Pituitary Diseases / cerebrospinal fluid. Pituitary Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Spinal Puncture / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688833.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cerebrospinal Fluid Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Neurofilament Proteins; 0 / neurofilament protein L; 0 / tau Proteins
  •  go-up   go-down


37. Turedi A, Demir C, Dilek I: Assessment of malnutrition in adult acute leukemia cases. Asian Pac J Cancer Prev; 2010;11(3):703-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of malnutrition in adult acute leukemia cases.
  • METHODS: 54 cases, consisting of 40 patients with acute myeloblastic leukemia (AML) and 14 patients with acute lymphoblastic leukemia (ALL) were included to the study, where further 34 healthy subjects were also recruited.
  • CONCLUSIONS: Prevalence of malnutrition was seen at higher percentage in adult acute leukemia cases, which was increased during the course of treatment, and TST measurement was better in establishing malnutrition.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Malnutrition / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Body Mass Index. Case-Control Studies. Female. Humans. Male. Nutrition Assessment. Prevalence. Prognosis. Risk Factors. Skinfold Thickness

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039039.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


38. Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M: Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood; 2005 Dec 15;106(13):4303-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
  • The prognostic significance of angiogenic factors in adult acute lymphoblastic leukemia (ALL) remains ambiguous.
  • We therefore analyzed the impact of angiogenic factor levels on overall survival of newly diagnosed adult ALL patients.
  • [MeSH-major] Angiogenesis Inducing Agents / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123221.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Receptors, Interleukin-1; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


39. Lipshultz SE: Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol; 2006 Jun;33(3 Suppl 8):S8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of anthracyclines in the treatment of acute lymphoblastic leukemia is limited by associated cardiotoxic effects, which can result in cardiomyopathy and congestive heart failure, and may be irreversible.
  • There is evidence that dexrazoxane significantly reduces the cardiotoxicity associated with anthracyclines such as daunorubicin, doxorubicin, and epirubicin in adult patients with a wide range of tumor types.
  • A study of the efficacy of dexrazoxane in reducing doxorubicin-induced cardiotoxicity in children and adolescents with high-risk acute lymphoblastic leukemia, showed that significantly fewer dexrazoxane-treated patients (21%) had elevated serum cardiac troponin (a biomarker of acute myocardial injury) levels than patients treated with chemotherapy alone (50%; P <.001).
  • [MeSH-minor] Adolescent. Adult. Cardiovascular Agents / therapeutic use. Child. Disease Progression. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Razoxane / therapeutic use. Risk Factors. Survivors

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781284.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Cardiovascular Agents; 5AR83PR647 / Razoxane
  • [Number-of-references] 50
  •  go-up   go-down


40. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


41. Imahashi N, Ohashi H, Arita K, Kitamura K, Takahashi T, Ozawa Y, Miyamura K: Acute lymphoblastic leukemia of male-recipient origin demonstrating female karyotype after cord blood transplantation. J Clin Oncol; 2010 Dec 20;28(36):e750-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia of male-recipient origin demonstrating female karyotype after cord blood transplantation.
  • [MeSH-major] Chimera. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Cord Blood Stem Cell Transplantation. Female. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Recurrence. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855841.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Gurney JG, Donohue JE, Ness KK, O'Leary M, Glasser SP, Baker KS: Health knowledge about symptoms of heart attack and stroke in adult survivors of childhood acute lymphoblastic leukemia. Ann Epidemiol; 2007 Oct;17(10):778-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health knowledge about symptoms of heart attack and stroke in adult survivors of childhood acute lymphoblastic leukemia.
  • PURPOSE: Children with acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, have a 5-year survival rate of better than 80%.
  • METHODS: As part of a clinical follow-up study of 70 young adult survivors of childhood ALL, we evaluated the degree to which this high-risk group differed in knowledge about symptoms of heart attack and stroke from that of a population-based comparison group frequency-matched by age, sex, and body mass index.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Stroke. 2001 Jan;32(1):63-9 [11136916.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Cancer Treat Rev. 2002 Aug;28(4):195-214 [12363460.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3494S-3503S [12421876.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 May 7;53(17):359-62 [15129192.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Ann Med. 1997 Oct;29(5):353-5 [9453278.001]
  • [Cites] Am Heart J. 2005 Sep;150(3):392-400 [16169313.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6508-15 [16170160.001]
  • [Cites] Nat Clin Pract Oncol. 2004 Nov;1(1):26-31 [16264796.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2638-42 [16258932.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):143-8 [16317758.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):169-73 [16320315.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):149-58 [16369924.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1829-37 [16541445.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 May 19;55(19):529-32 [16708056.001]
  • [Cites] Circulation. 2006 Jul 11;114(2):168-82 [16801458.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Clin Oncol. 2006 Nov 10;24(32):5160-5 [17093280.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5277-82 [17088567.001]
  • [Cites] Circulation. 2007 Feb 6;115(5):e69-171 [17194875.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jun 15;48(7):723-6 [17226844.001]
  • (PMID = 17662616.001).
  • [ISSN] 1047-2797
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000400; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCRR NIH HHS / RR / M01-RR00400; United States / NCI NIH HHS / CA / K23 CA085503; United States / NCI NIH HHS / CA / CA106778-01; United States / NCI NIH HHS / CA / R21 CA106778; United States / NCI NIH HHS / CA / R21-CA106778; United States / NCI NIH HHS / CA / K23-CA85503; United States / NCRR NIH HHS / RR / M01 RR000400-370599; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCRR NIH HHS / RR / RR000400-385932; United States / NCRR NIH HHS / RR / M01 RR000400-385932; United States / NCRR NIH HHS / RR / RR000400-370599; United States / NCI NIH HHS / CA / R21 CA106778-01; United States / NCI NIH HHS / CA / CA106778-02; United States / NCI NIH HHS / CA / R21 CA106778-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS31507; NLM/ PMC2036017
  •  go-up   go-down


43. Thomas X, Pavan L, Le QH: [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview]. Bull Cancer; 2008 Jul-Aug;95(7):707-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult acute lymphoblastic leukemia with central nervous system involvement: an overview].
  • At the time of diagnosis, central nervous system (CNS) involvement is identified in less than 10% of adult acute lymphoblastic leukemia (ALL).
  • Adult ALL with CNS recurrence remains of poor prognosis and is generally associated with a systemic and medullary relapse.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Cytarabine / adverse effects. Cytarabine / therapeutic use. Humans. Meningeal Neoplasms. Methotrexate / adverse effects. Methotrexate / therapeutic use. Prognosis. Radiotherapy / adverse effects. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 109
  •  go-up   go-down


44. Gao F, Chia KS, Machin D: On the evidence for seasonal variation in the onset of acute lymphoblastic leukemia (ALL). Leuk Res; 2007 Oct;31(10):1327-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the evidence for seasonal variation in the onset of acute lymphoblastic leukemia (ALL).
  • Inconsistent seasonal patterns in peak presentation of acute lymphoblastic leukemia have been reported but no formal synthesis of published reports has been attempted to date.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Seasons
  • [MeSH-minor] Adolescent. Adult. Age Factors. Age of Onset. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481728.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 35
  •  go-up   go-down


45. Shafer D, Wu H, Al-Saleem T, Reddy K, Borghaei H, Lessin S, Smith M: Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol; 2008 Sep;144(9):1155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature.
  • BACKGROUND: Precursor B-cell lymphoblastic lymphoma (B-LBL) is an uncommon high-grade neoplasm of immature B cells.
  • In contrast to the more common lymphoblastic lymphoma of T-cell lineage, B-LBL can be an extranodal disease, with a propensity to involve skin and bone.
  • Fluorescence in situ hybridization studies, not previously reported in primary cutaneous B-LBL to our knowledge, demonstrated rearrangement of the MLL gene in one patient and possible hyperdiploidy in the other, both reported in precursor acute lymphoblastic leukemia.
  • Precursor B-cell lymphoblastic lymphoma is more common in children and in young adults, with a tropism for the head and neck region.
  • Although there is a suggestion in a limited number of patients that abbreviated therapy may provide long-term disease control, the risk of relapse remains significant, particularly if a patient's condition is misdiagnosed and the patient is treated as having mature B-cell lymphoma.
  • In the absence of prospective studies for this population, patients with B-LBL are treated currently with intensive acute lymphoblastic leukemia regimens.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Back. Cytogenetic Analysis. Diploidy. Forehead. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Scalp. Skin / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794461.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 25
  •  go-up   go-down


46. Zunino SJ, Storms DH, Ducore JM: Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett; 2010 Oct 1;296(1):49-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11).
  • Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse.
  • SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry.
  • The level of P-glycoprotein in SEM cells was increased 3-fold by vincristine treatment compared to PBS-treated mice.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Leuk Lymphoma. 2005 May;46(5):681-91 [16019505.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7 [19034447.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4100-8 [12010813.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Dec 30;141(3):956-62 [2880583.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):393-8 [2891436.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1597-600 [2595371.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3658-61 [8101765.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):275-83 [8199015.001]
  • [Cites] Blood. 1996 May 1;87(9):3892-8 [8611717.001]
  • [Cites] Leukemia. 1996 Mar;10(3):558-63 [8642875.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1135-46 [8695830.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4332-7 [8813118.001]
  • [Cites] Blood. 1997 Sep 1;90(5):2015-9 [9292537.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Crit Rev Clin Lab Sci. 1998 Feb;35(1):1-57 [9532418.001]
  • [Cites] Blood. 1998 Jun 1;91(11):3995-4019 [9596644.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):875-93 [17671794.001]
  • (PMID = 20381955.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA122117; United States / NCI NIH HHS / CA / 1R21CA122117-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.1.2.15 / UCHL1 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  • [Other-IDs] NLM/ NIHMS195255; NLM/ PMC2906616
  •  go-up   go-down


47. Vitale A, Guarini A, Chiaretti S, Foà R: The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol; 2006 Nov;18(6):652-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing scene of adult acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The review focuses on the most recent advances in the diagnostic and prognostic work-up of adult acute lymphoblastic leukemia (ALL) and its implications in the clinical management of the disease.
  • SUMMARY: Recent biologic advancements are progressively realising the possibility of designing targeted and individualized therapeutic strategies according to the more refined, molecularly defined features of leukemic cells and the presence or absence of residual disease in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988590.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 104
  •  go-up   go-down


48. Berceanu A, Toujani S, Da Costa L, Itzhar N, Lapusan S, Bernheim A, Ribrag V: An unusual case of a lymphoblastic lymphoma with initial bilateral breast lesions but with c-myc and bcl-2 rearrangements. Leuk Lymphoma; 2007 Feb;48(2):415-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of a lymphoblastic lymphoma with initial bilateral breast lesions but with c-myc and bcl-2 rearrangements.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gene Rearrangement. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Diagnosis, Differential. Female. Humans. Translocation, Genetic

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325907.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


49. Goldstone AH: Transplants in Adult ALL--? Allo for everyone. Biol Blood Marrow Transplant; 2009 Jan;15(1 Suppl):7-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplants in Adult ALL--? Allo for everyone.
  • The large MRC/ECOG adult acute lymphoblastic leukemia (ALL) study establishes the value of sibling donor allogeneic transplant in standard-risk patients demonstrating superior outcome to conventional chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147069.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


50. Essa EA, El Halim SM, Abo-Elenin A, El Bendary A, Abdou SH, Farag W: Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia. Egypt J Immunol; 2007;14(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proliferation of malignant lymphohematopoietic cells is thought to be regulated by a number of surface molecules on tumour cells whose expression may contribute to neoplastic transformation.
  • In this work, reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the gene expression (mRNA) of CD30 variant (CD30v) and CD30 Ligand (CD30L) on the peripheral blood mononuclear cells (PBMCs) of 15 healthy individuals as a control group, 15 patients with newly diagnosed acute myeloid leukemia (AML) and 15 patients with newly diagnosed acute lymphocytic leukemia (ALL).

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689277.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CD30 Ligand; 0 / RNA, Messenger
  •  go-up   go-down


51. Kletting P, Kull T, Reske SN, Glatting G: Comparing time activity curves using the Akaike information criterion. Phys Med Biol; 2009 Nov 7;54(21):N501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Antigens, CD / chemistry. Cell Adhesion Molecules / chemistry. Female. Humans. Indium Radioisotopes / pharmacokinetics. Kinetics. Leukemia, Myeloid, Acute / radiotherapy. Male. Middle Aged. Models, Statistical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiopharmaceuticals / pharmacokinetics. Yttrium Radioisotopes / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820266.001).
  • [ISSN] 1361-6560
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  •  go-up   go-down


52. Wei L, Zuo H, Sun X, Liu T, Guo M, Liu G, Sun Q, Qiao J, Wang D, Yu C, Hu K, Dong Z, Ai H: Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients. Int J Hematol; 2010 May;91(4):652-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical studies have shown that NST has better therapeutic results with chronic myelogenous leukemia (CML) than acute leukemia (AL), but whether the generation of graft-versus-leukemia (GVL) effects is different between AL and CML patients early after NST has not yet been studied, so we used a pentamer-staining technique in combination with ICCS to detect WT1(+)CD8(+)CTL/WT1(+)Tc1 and WT1(+)Th1 cells in these two groups of patients.
  • Results showed that the emergence time of WT1(+)CD(8) (+)CTL/WT1(+)Tc1 cells after NST in AL patients was similar to that in CML patients (P = 0.58), while the emergence time of WT1(+)Th1 cells after NST in AL patients was shorter than in CML patients (P = 0.047).
  • Furthermore, the peak proportions of WT1(+)CD(8) (+)CTL/WT1(+)Tc1 (P > 0.05) and WT1(+)Th1 (P > 0.05) cells were similar between AL and CML patients, and the increased rates (P > 0.05) and elevated levels (P > 0.05) of WT1-specific T cells were not statistically different between the groups after G-CSF mobilized donor mononuclear cell infusion.
  • [MeSH-major] Graft vs Leukemia Effect / physiology. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. T-Lymphocyte Subsets / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adult. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Child. Female. Flow Cytometry. Gene Expression Regulation, Leukemic. Humans. Male. Middle Aged. Myeloablative Agonists. Th1 Cells / metabolism. Th1 Cells / pathology. Transplantation Chimera. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001 Dec;9(4):333-337 [12578574.001]
  • [Cites] Biol Blood Marrow Transplant. 1996 Oct;2(3):118-25 [9199754.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7476-82 [17189421.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Curr Opin Hematol. 1995 Nov;2(6):423-30 [9372031.001]
  • [Cites] Haematologica. 2007 Mar;92(3):414-7 [17339194.001]
  • [Cites] Int J Hematol. 2007 Oct;86(3):275-81 [17988996.001]
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):601-8 [15756285.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Br J Haematol. 1986 Apr;62(4):757-62 [2938618.001]
  • [Cites] Ter Arkh. 1999;71(7):27-32 [10481864.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1789-97 [15385924.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Br J Haematol. 1988 Jun;69(2):239-45 [3291930.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):550-9 [17448914.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9387-93 [16314618.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • (PMID = 20376582.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 0 / WT1 Proteins
  •  go-up   go-down


53. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol; 2009 Jul 20;27(21):3472-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. Treatment Failure
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Dasatinib. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Treatment Outcome. Young Adult


54. Singh T, Satheesh CT, Madhumathi DS, Goyal M, Rajeev LK, Lakshmaiah KC, Suresh TM, Babu KG: Turbid serum in a patient of acute lymphoblastic leukemia on treatment--what to look for? J Cancer Res Ther; 2009 Jul-Sep;5(3):219-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Turbid serum in a patient of acute lymphoblastic leukemia on treatment--what to look for?
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Cholesterol / blood. Humans. Hypoglycemic Agents / therapeutic use. Male. Triglycerides / blood

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841569.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypoglycemic Agents; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


55. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, Picardi M, Specchia G, Mancini M, Cuneo A, Mecucci C, Martinelli G, Saglio G, Rotoli B, Mandelli F, Salvatore F, Foà R, GIMEMA group: Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia; 2005 Apr;19(4):628-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has a dismal prognosis.
  • Our data indicate that, as already shown in children, adult Ph+ ALL patients have a heterogeneous sensitivity to treatment, and that early quantification of residual disease is a prognostic parameter in this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / genetics. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Asparaginase / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Neoplasm, Residual / genetics. Neoplasm, Residual / mortality. Predictive Value of Tests. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744351.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


56. Aoki CA, Bowlus CL, Rossaro L: An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction. Dig Liver Dis; 2005 Mar;37(3):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction.
  • We describe an adult case of acute lymphoblastic leukaemia presenting as an acute hepatitis.
  • Due to the elevation in the patient's transaminases and bilirubin, standard acute lymphoblastic leukaemia induction therapy could not be used.
  • [MeSH-major] Liver Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888287.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone
  •  go-up   go-down


57. Wang X, Yang S, Tu P, Li R: A case of Langerhans cell histiocytosis in an adult with initial symptoms confined to the skin. Int J Dermatol; 2010 Mar;49(3):337-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Langerhans cell histiocytosis in an adult with initial symptoms confined to the skin.
  • [MeSH-minor] Dexamethasone / therapeutic use. Etoposide / therapeutic use. Fatal Outcome. Humans. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Vinblastine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465678.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


58. Chan-Tack KM: Fatal Trichosporon asahii septicemia in a Guatemalan farmer with acute lymphoblastic leukemia. South Med J; 2005 Sep;98(9):954-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal Trichosporon asahii septicemia in a Guatemalan farmer with acute lymphoblastic leukemia.
  • [MeSH-major] Agriculture. Mycoses / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Sepsis / microbiology. Trichosporon / isolation & purification
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheterization, Peripheral. Emigration and Immigration. Fatal Outcome. Fever / microbiology. Guatemala / ethnology. Humans. Male. Neutropenia / etiology. Pyrimidines / therapeutic use. Triazoles / therapeutic use. United States. Urease / isolation & purification. Voriconazole. Yeasts / enzymology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217998.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; EC 3.5.1.5 / Urease; JFU09I87TR / Voriconazole
  •  go-up   go-down


59. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagués JM, Espinosa AB, Lopez-Berges MC, García-Sanz R, Gutierrez NC, Hernandez JM, Romero M, Osuna CS, Giralt M, Barbon M, San Miguel JF, Orfao A: Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia; 2005 May;19(5):713-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics.
  • Philadelphia-positive (Ph(+)) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a genetically heterogeneous disease with a very poor prognosis.
  • In this study, we analyzed the frequency of supernumerary Ph, trisomy 8, monosomy 7, and del(9p21) by FISH and its relationship with the characteristics of the disease, in 46 BCR/ABL(+) adult BCP-ALL patients.
  • [MeSH-major] Burkitt Lymphoma / genetics. Fusion Proteins, bcr-abl / genetics. Genetic Heterogeneity. Immunophenotyping
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. DNA / genetics. Disease-Free Survival. Female. Flow Cytometry / methods. Humans. In Situ Hybridization, Fluorescence / methods. Interphase. Karyotyping. Male. Middle Aged. Ploidies. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15789066.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


60. Lasa A, Serrano E, Carricondo M, Carnicer MJ, Brunet S, Badell I, Sierra J, Aventín A, Nomdedéu JF: High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias. Ann Hematol; 2008 Mar;87(3):205-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias.
  • Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells.
  • Ectopic CD66 expression is commonly detected in B-cell lineage acute lymphoblastic leukemia (ALL).
  • It remains to be investigated whether these CEACAM disturbances provide growth advantages to tumoral cells by inhibiting the anoikis process.
  • [MeSH-major] Antigens, CD / biosynthesis. Blast Crisis / metabolism. Cell Adhesion Molecules / biosynthesis. Gene Expression Regulation, Leukemic. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Adhesion / genetics. Cell Movement / genetics. Female. GPI-Linked Proteins. Genes, abl / genetics. Humans. Male. Middle Aged. Neprilysin / biosynthesis. Neprilysin / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909799.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CEACAM6 protein, human; 0 / CEACAM8 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


61. Zhou FL, Zhang WG, Su ZX, Meng X, Tian W: [Relationship between oxidative stress and depression in patients with acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):872-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between oxidative stress and depression in patients with acute leukemia].
  • This study was aimed to investigate the relationships between oxidative stress and depression in patients with acute leukemia.
  • Ninety two cases of acute leukemia were randomly enrolled in the study.
  • Depressive disorder was assessed by self-rating depression scales (SDS) and multiple items questionaires.
  • The total anti-oxidation capability (T-AOC), reactive oxygen species (ROS) and superoxide dismutase (SOD) activities, as well as malondialdehyde (MDA) and nitric oxide (NO) levels were measured in pre-treatment periods.
  • Meanwhile, the steady state level of human 8-hydroxyguanine glycosylase (hOGG1) mRNA transcript was monitored by quantitative real-time PCR.
  • The results showed that the defence of antioxidant system was impaired in patients with acute leukemia.
  • The incidence of depression was 47.83% in 92 cases.
  • T-AOC and SOD activities were significantly decreased in patients with depression, while ROS, NO, MDA levels and hOGG1 mRNA expression were reverse of the former.
  • It revealed that depression positively correlated with course of disease and hOGG1, and negatively correlated with T-AOC.
  • It is concluded that oxidative damage occurs in patients with acute leukemia, moreover, lower antioxidant defences exist in depressive patients.
  • These results underscore the notion that oxidative stress may promote the development of depression.

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Depression.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096879.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


62. Sinclair P, Harrison CJ, Jarosová M, Foroni L: Analysis of balanced rearrangements of chromosome 6 in acute leukemia: clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new recurrent translocation, t(6;7)(q23;q32 through 36). Haematologica; 2005 May;90(5):602-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study we investigated the significance of novel translocations and inversions of 6q in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
  • [MeSH-major] Chromosome Breakage. Chromosome Inversion / genetics. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 7 / genetics. Genes, myb. Leukemia, Myeloid / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adaptor Proteins, Signal Transducing / genetics. Adolescent. Bone Marrow Cells / ultrastructure. Child. Child, Preschool. Chromosome Banding. Clone Cells / pathology. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Male. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921375.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / AHI1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


63. Ottmann OG, Pfeifer H: Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program; 2009;:371-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008223.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Bispecific; 0 / Benzamides; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 4FR53SIF3A / blinatumomab; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


64. Bassan R: Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Haematologica; 2005 Oct;90(10):1299
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Clinical Trials, Phase III as Topic / methods. Disease Management. Humans. Stem Cell Transplantation / methods. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2005 Oct;90(10):1346-56 [16219571.001]
  • (PMID = 16219555.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Potenza L, Riva G, Luppi M, Torelli G: Pneumonia in acute leukaemia: blossoming culprits. Br J Haematol; 2005 Feb;128(4):411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Opportunistic Infections / complications. Pneumonia, Bacterial / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Pseudomonas Infections / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686449.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S: Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion; 2006;74(1):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.
  • L-Asparaginase is commonly used in combination chemotherapy of both pediatric and adult acute lymphoblastic leukemia.
  • We report here an adult patient who developed mixed liver injury and predominantly microvesicular hepatic steatosis while being treated with L-asparaginase for acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Liver Failure / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988508.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


67. Jacobsen E, LaCasce A: Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2006 Jul;6(7):699-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
  • This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma. Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Child. Female. Humans. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805709.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


68. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R: PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol; 2005 Aug;79(4):257-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, PRAME mRNA using real-time RT-PCR was studied in 74 adult cases with acute leukemia-68 had de-novo acute leukemia, 3 had chronic myeloid leukemia-blastic crisis (CML-BC), and 3 had myelodysplastic/myeloproliferative syndrome-blastic transformation (MDS/MPD-BT)-and the results were compared with 30 age-matched healthy volunteers.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. RNA, Messenger / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Blast Crisis / blood. Blast Crisis / diagnosis. Blast Crisis / metabolism. DNA, Complementary / analysis. Female. Humans. Leukocytes / metabolism. Male. Middle Aged. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / metabolism. Myeloproliferative Disorders / blood. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / metabolism. Prognosis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16044453.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / PRAME protein, human; 0 / RNA, Messenger
  •  go-up   go-down


69. Amirghofran Z, Daneshbod Y, Gholijani N: Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome. Oncol Res; 2009;17(10):447-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome.
  • The present study was performed to find the importance of two myeloid (CD13 and CD33) antigens aberrantly expressed on the blasts of acute lymphoblastic leukemia (ALL) patients and Bcl-2 expression in relation to clinical and biological features and treatment outcome.
  • Presence of these markers together on the leukemic cells was associated with a poorer response to therapy and may implicate modified therapeutic strategies in the patients.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Bone Marrow / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Sialic Acid Binding Ig-like Lectin 3. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725224.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


70. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed. Prescrire Int; 2009 Feb;18(99):3-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
  • 1) Acute T-lymphoblastic leukaemia and T-lymphoblastic lymphoma are closely related malignant haemopathies.
  • 3) Clinical evaluation of nelarabine in this setting includes two non-comparative trials in accordance with the conditions of the marketing terms, one in 48 children and the other in 28 adults.
  • But this type of non-comparative trial cannot demonstrate whether a specific drug increases survival time compared with existing alternatives;.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Drug Approval. Europe. Humans. Orphan Drug Production. Recurrence

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382393.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Arabinonucleosides
  •  go-up   go-down


71. Burton A: Aminopterin might be safe in ALL. Lancet Oncol; 2007 Oct;8(10):873
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aminopterin / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans

  • Hazardous Substances Data Bank. AMINOPTERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974054.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] JYB41CTM2Q / Aminopterin
  •  go-up   go-down


72. Au WY, Chan E, Lie AK: Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status. Am J Hematol; 2007 Jun;82(6):495
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] HTLV-I Infections / prevention & control. Hematopoietic Stem Cell Transplantation / adverse effects. Human T-lymphotropic virus 1 / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Tissue Donors
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Blotting, Western. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Piperazines / therapeutic use. Polymerase Chain Reaction. Pyrimidines / therapeutic use. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929539.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


73. Reutenauer S, Albucher JF, Pariente J, Dumas H, Milioto O, Attal M, Recher C, Huguet F: Posterior reversible encephalopathy syndrome: two cases in young adults with acute lymphoblastic leukemia. Leuk Res; 2009 Jun;33(6):e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posterior reversible encephalopathy syndrome: two cases in young adults with acute lymphoblastic leukemia.
  • [MeSH-major] Brain Diseases / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Female. Humans. Male


74. Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM: Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica; 2008 Aug;93(8):1161-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents and young adults in Finland.
  • BACKGROUND: Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than adult therapeutic protocols.
  • There are different biological subtypes of acute lymphoblastic leukemia with distinct features and prognoses; the distribution of these subtypes is not well known among adolescents.
  • We, therefore, studied acute lymphoblastic leukemia in adolescents and young adults aged 10 to 25 years in Finland.
  • DESIGN AND METHODS: This population-based study included 225 consecutive patients aged 10-25 years diagnosed with acute lymphoblastic leukemia during 1990-2004.
  • The 5-year event-free survival was 67% for the pediatric treatment group and 60% for the adult treatment group (p=n.s.).
  • CONCLUSIONS: Unlike all previous studies, we found that the outcome of adolescents and young adults with acute lymphoblastic leukemia treated with pediatric or adult therapeutic protocols was comparable.
  • The success of the adult acute lymphoblastic leukemia therapy emphasizes the benefit of central referral of patients to academic centers and adherence to research protocols.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Blast Crisis. Child. Disease-Free Survival. Female. Finland. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Count. Male. Phenotype. Philadelphia Chromosome. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Aug;93(8):1124-8 [18669975.001]
  • (PMID = 18556413.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


75. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL: A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia; 2009 Dec;23(12):2259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds).
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Child. Child, Preschool. Drug-Induced Liver Injury. Hematopoietic Stem Cell Transplantation. Humans. Infant. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Maximum Tolerated Dose. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741725.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 6PLQ3CP4P3 / Etoposide; 762RDY0Y2H / clofarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


76. Rapała K, Walczak P, Truszczyńska A: [Orthopedic diagnostic and therapeutic problems in avascular poststeroid necrosis of femur head in the course acute lymphoblastic leukemia--description of 3 cases]. Chir Narzadow Ruchu Ortop Pol; 2010 Mar-Apr;75(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orthopedic diagnostic and therapeutic problems in avascular poststeroid necrosis of femur head in the course acute lymphoblastic leukemia--description of 3 cases].
  • INTRODUCTION: Chronic use of steroids in acute lymphoblastic leukemia is a significant supportive therapy.
  • DESCRIPTION OF CASES AND RESULTS: Authors described chemotherapy of acute lymphoblastic leukemia according to established program.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Femur Head Necrosis / chemically induced. Femur Head Necrosis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Arthroplasty, Replacement, Hip. Decompression, Surgical / methods. Delayed Diagnosis. Female. Humans. Male. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20695186.001).
  • [Journal-full-title] Chirurgia narzadów ruchu i ortopedia polska
  • [ISO-abbreviation] Chir Narzadow Ruchu Ortop Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


77. Ucisik-Akkaya E, Davis CF, Gorodezky C, Alaez C, Dorak MT: HLA complex-linked heat shock protein genes and childhood acute lymphoblastic leukemia susceptibility. Cell Stress Chaperones; 2010 Sep;15(5):475-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA complex-linked heat shock protein genes and childhood acute lymphoblastic leukemia susceptibility.
  • To systematically evaluate their associations with childhood acute lymphoblastic leukemia (ALL), we examined the three functional single nucleotide polymorphisms (SNPs) rs2227956 (T493M) in HSPA1L, rs1043618 in HSPA1A 5'UTR, and rs1061581 (Q351Q) in HSPA1B by TaqMan assays or polymerase chain reaction-restriction fragment length polymorphism in 114 ALL cases and 414 controls from Wales (UK), in 100 Mexican Mestizo ALL cases and 253 controls belonging to the same ethnic group, and in a panel of 82 HLA-typed reference cell line samples.
  • [MeSH-major] HSP70 Heat-Shock Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Genetic Predisposition to Disease / genetics. Genotype. Haplotypes. Humans. Male. Polymorphism, Restriction Fragment Length / genetics. Polymorphism, Single Nucleotide / genetics. Sex Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Hematol. 1999 Nov;27(11):1627-36 [10560910.001]
  • [Cites] Allergy Proc. 1992 Sep-Oct;13(5):243-50 [1483573.001]
  • [Cites] Nat Med. 2000 Apr;6(4):435-42 [10742151.001]
  • [Cites] Intensive Care Med. 2000 Aug;26(8):1139-43 [11030172.001]
  • [Cites] Arthritis Rheum. 2001 Feb;44(2):286-95 [11229458.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):672-8 [11241233.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):184-7 [11796767.001]
  • [Cites] Tissue Antigens. 1993 Jan;41(1):15-9 [8096093.001]
  • [Cites] Scand J Immunol. 1993 Nov;38(5):491-5 [7901896.001]
  • [Cites] Leuk Lymphoma. 1994 Jan;12(3-4):211-22 [7909466.001]
  • [Cites] Cell Stress Chaperones. 1997 Sep;2(3):141-55 [9314601.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1489-96 [9338474.001]
  • [Cites] Immunity. 1998 Jun;8(6):657-65 [9655479.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):561-5 [9744491.001]
  • [Cites] Blood. 1999 Jul 15;94(2):694-700 [10397736.001]
  • [Cites] Cell Death Differ. 2005 Jan;12(1):38-51 [15592361.001]
  • [Cites] Cell Stress Chaperones. 2005 Summer;10(2):86-103 [16038406.001]
  • [Cites] Immunogenetics. 2006 Apr;58(2-3):113-21 [16547745.001]
  • [Cites] Ann N Y Acad Sci. 2006 May;1067:301-8 [16804002.001]
  • [Cites] J Appl Physiol (1985). 2006 Aug;101(2):566-75 [16690792.001]
  • [Cites] Ann Hematol. 2006 Aug;85(8):535-41 [16710717.001]
  • [Cites] Genes Immun. 2006 Sep;7(6):450-67 [16791278.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1733-7 [16985037.001]
  • [Cites] Cell Stress Chaperones. 2006 Autumn;11(3):208-15 [17009593.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):15-27 [16931602.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2373-81 [17332370.001]
  • [Cites] Front Biosci. 2007;12:4504-13 [17485392.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2035-40 [17675458.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):926-35 [17580361.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):767-74 [17700693.001]
  • [Cites] Ann N Y Acad Sci. 2007 Oct;1113:192-201 [17978282.001]
  • [Cites] Medicine (Baltimore). 2008 Mar;87(2):87-98 [18344806.001]
  • [Cites] Cardiology. 2008;110(1):45-52 [17934269.001]
  • [Cites] Mol Med. 2008 Jul-Aug;14(7-8):517-27 [18431462.001]
  • [Cites] Cell Stress Chaperones. 2008 Sep;13(3):253-62 [18335321.001]
  • [Cites] Int J Immunogenet. 2008 Dec;35(6):465-73 [19046306.001]
  • [Cites] Dig Dis Sci. 2009 Jan;54(1):70-4 [18478330.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):3-15 [19100363.001]
  • [Cites] Ann Hum Genet. 2009 Jan;73(1):95-108 [19040659.001]
  • [Cites] Eur J Hum Genet. 2009 Mar;17(3):329-35 [18813331.001]
  • [Cites] PLoS One. 2009;4(3):e4851 [19333379.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1174-82 [19293308.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1001-5 [19684603.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1006-10 [19684604.001]
  • [Cites] Biochim Biophys Acta. 2010 Feb;1802(2):292-300 [19897031.001]
  • [Cites] Trends Immunol. 2002 Mar;23(3):130-5 [11864840.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15028-34 [11836257.001]
  • [Cites] Eur J Hum Genet. 2002 Apr;10(4):259-65 [12032734.001]
  • [Cites] Genes Immun. 2002 Aug;3(5):263-9 [12140744.001]
  • [Cites] Genome Res. 2003 Dec;13(12):2621-36 [14656967.001]
  • [Cites] J Med Virol. 2004 Sep;74(1):180-90 [15258986.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6429-44 [15322515.001]
  • [Cites] Intensive Care Med. 2004 Sep;30(9):1761-7 [15232679.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3957 [10627122.001]
  • (PMID = 20012387.001).
  • [ISSN] 1466-1268
  • [Journal-full-title] Cell stress & chaperones
  • [ISO-abbreviation] Cell Stress Chaperones
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / HSPA1A protein, human; 0 / HSPA1B protein, human; 0 / HSPA1L protein, human
  • [Other-IDs] NLM/ PMC3006629
  •  go-up   go-down


78. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, Ishida T, Tanaka T: Marked increase of normal blast morphologically mimicking leukemic clone in acute lymphoblastic leukemia patient following G-CSF therapy. Int J Hematol; 2008 Nov;88(4):468-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked increase of normal blast morphologically mimicking leukemic clone in acute lymphoblastic leukemia patient following G-CSF therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphocyte Activation / drug effects. Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Recovery of Function / drug effects. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lab Haematol. 2004 Oct;26(5):359-62 [15485468.001]
  • [Cites] Blood. 1993 Jan 15;81(2):281-92 [8422455.001]
  • [Cites] Am J Hematol. 1996 Jun;52(2):123-4 [8638638.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3485-6 [7685207.001]
  • [Cites] Clin Lab Haematol. 1998 Feb;20(1):49-51 [9681211.001]
  • [Cites] Acta Paediatr Jpn. 1995 Feb;37(1):78-80 [7538724.001]
  • (PMID = 18839272.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, Tedeschi A, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R: A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood; 2005 May 1;105(9):3434-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.
  • The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 0496 protocol, through the central handling of bone marrow samples at presentation, allowed us to combine cytogenetic and molecular information on a large series of adults with acute lymphoblastic leukemia (ALL) treated homogeneously, enabling us to define as broadly as possible their genetic profile and to determine the impact on outcome of the cytogenetic-molecular signature.
  • This study highlights the importance of a combined cytogenetic-molecular profiling of adult ALL at presentation as a critical independent determinant of their outcome, providing further evidence of the necessity of a risk-adapted therapeutic algorithm for an optimal management of these patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Chromosome Aberrations. Classification. Cytogenetic Analysis. Female. Humans. Karyotyping. Male. Middle Aged. Oncogene Proteins, Fusion / analysis. Ploidies. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome


80. Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, Zühlsdorf M, Müller-Tidow C, Berdel WE: Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol; 2008 Sep;19(9):1644-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis.
  • BACKGROUND: Oral mucositis is a frequent problem after high-dose methotrexate (HD-MTX), impairing patient's quality of life, leading to higher rates of infections and delaying subsequent chemotherapy.
  • This report describes the effect of palifermin in patients treated within the GMALL-B-ALL 2002 protocol containing HD-MTX who developed a severe mucositis in cycle A1/B1.
  • PATIENTS AND METHODS: Ten patients, all with World Health Organization grades III-IV oral mucositis in cycles A1/B1, obtained palifermin with subsequent similar or identical cycles to reduce mucositis.
  • Thus, patients serve as their own control for efficacy of palifermin.
  • RESULTS: All 10 patients developed grades III-IV mucositis in cycles A1/B1 without palifermin, whereas only two of 10 developed grades III-IV mucositis in corresponding cycles A2/B2 with palifermin.
  • Only four of 10 patients showed infections in the cycles with palifermin compared with 10 of 10 patients without palifermin.
  • The duration of mucositits in patients who acquired a higher grade mucositis despite treatment with palifermin could be reduced from 12.9 days (median) without to 11 days with palifermin.
  • The amount of i.v. opioid analgetics could be significantly reduced.
  • CONCLUSION: Palifermin might reduce the incidence, severeness and duration of oral mucositis in HD-MTX-based chemotherapy and may influence clinical sequelae such as infection and quality of life.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453519.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 126469-10-1 / Fibroblast Growth Factor 7; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, Zilberman I, Miron S, Leubovic A, Slavin S, Or R: Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant; 2005 Dec;36(12):1097-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bone Marrow Transplantation. Child. Female. Gastrointestinal Tract / pathology. Humans. Infection. Liver / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Primary Myelofibrosis / therapy. Skin / pathology. Skin Abnormalities / therapy. T-Lymphocytes / metabolism. Time Factors. Transplantation Conditioning. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247429.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Steroids; ELK3V90G6C / alefacept
  •  go-up   go-down


82. Bacher U, Schnittger S, Grüneisen A, Haferlach T, Kern W, Haferlach C: Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. Cancer Genet Cytogenet; 2009 Jan 15;188(2):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further describe structural anomalies involving the 1q21 and 1q32 breakpoints, we present four cases with an inverted dup(1)(q32q21): three in B-cell precursor acute lymphoblastic leukemia (ALL) and one in MDS of the subtype refractory cytopenia with multilineage dysplasia and ringed sideroblasts.
  • [MeSH-minor] Adult. Aged. Chromosome Banding. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Trisomy

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100515.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


84. De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J: In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica; 2008 Apr;93(4):533-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
  • BACKGROUND: Activating NOTCH1 mutations are common in T-cell acute lymphoblastic leukemia.
  • We further documented the effects of gamma-secretase inhibitor treatment on T-cell acute lymphoblastic leukemia cell lines and tested whether combining gamma-secretase inhibitors with other anti-cancer drugs offers a therapeutic advantage.
  • DESIGN AND METHODS: The effect of gamma-secretase inhibitor treatment and combinations of gamma-secretase inhibitors with chemotherapy or glucocorticoids was assessed on T-cell acute lymphoblastic leukemia cell lines.
  • We sequenced NOTCH1 in T-cell acute lymphoblastic leukemia cases with ABL1 fusions and tested combinations of gamma-secretase inhibitors and the ABL1 inhibitor imatinib in a T-cell acute lymphoblastic leukemia cell line.
  • RESULTS: gamma-secretase inhibitor treatment for 5-7 days reversibly inhibited cell proliferation, caused cell cycle block in sensitive T-cell acute lymphoblastic leukemia cell lines, and caused differentiation of some T-cell acute lymphoblastic leukemia cell lines.
  • The cytotoxic effects of the chemotherapeutic agent vincristine were not significantly enhanced by addition of gamma-secretase inhibitors to T-cell acute lymphoblastic leukemia cell lines, but gamma-secretase inhibitor treatment sensitized cells to the effect of dexamethasone.
  • NOTCH1 mutations were identified in all T-cell acute lymphoblastic leukemia patients with ABL1 fusions and in a T-cell acute lymphoblastic leukemia cell line expressing NUP214-ABL1.
  • CONCLUSIONS: Short-term treatment of T-cell acute lymphoblastic leukemia cell lines with gamma-secretase inhibitors had limited effects on cell proliferation and survival.
  • Combinations of gamma-secretase inhibitors with other drugs may be required to obtain efficient therapeutic effects in T-cell acute lymphoblastic leukemia, and not all combinations may be useful.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Antineoplastic Agents / pharmacology. Benzodiazepinones / pharmacology. Carbamates / pharmacology. Dipeptides / pharmacology. Enzyme Inhibitors / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Apr;93(4):493-7 [18379008.001]
  • (PMID = 18322257.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 2-(((3,5-difluorophenyl)acetyl)amino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)propanamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Benzodiazepinones; 0 / Carbamates; 0 / DNA, Neoplasm; 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / L 685458; 0 / NOTCH1 protein, human; 0 / NUP214-ABL1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / Receptor, Notch1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8A1O1M485B / Imatinib Mesylate; EC 3.4.- / Amyloid Precursor Protein Secretases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


85. Seibel NL: Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program; 2008;:374-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls.
  • Survival of children with acute lymphoblastic leukemia (ALL) is often described as the success story for oncology.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074113.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 45
  •  go-up   go-down


86. Burmeister T, Schwartz S, Hummel M, Hoelzer D, Thiel E: No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms. Retrovirology; 2007;4:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms.
  • HTLV-I is the main causative agent in adult T-cell leukemia in endemic areas and some of the simian T-cell lymphotropic viruses have been implicated in the induction of malignant lymphomas in their hosts.
  • We used this PCR to detect Deltaretroviruses in samples from adult patients with a variety of rare T-cell neoplasms in Germany.
  • Fifty acute T-cell lymphoblastic leukemia (T-ALL) samples and 33 samples from patients with various rare mature T-cell neoplasms (T-PLL, Sézary syndrome and other T-NHL) were subsequently investigated.
  • [MeSH-major] Deltaretrovirus / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Adult. Base Sequence. DNA Primers. Humans. Molecular Sequence Data

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 Feb;75(3):1095-103 [11152482.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3556-9 [16873673.001]
  • [Cites] J Gen Virol. 2001 Sep;82(Pt 9):2205-13 [11514731.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):504-10 [15243924.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1297-305 [5408805.001]
  • [Cites] J Immunol. 1978 Mar;120(3):777-82 [344797.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):268-71 [6272125.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):658 [6125790.001]
  • [Cites] Science. 1982 Nov 5;218(4572):571-3 [6981847.001]
  • [Cites] Science. 1983 Feb 18;219(4586):856-9 [6600519.001]
  • [Cites] Lancet. 1983 Dec 24-31;2(8365-66):1495 [6140580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Feb;82(3):677-81 [2983308.001]
  • [Cites] Immunogenetics. 1992;35(1):1-8 [1345904.001]
  • [Cites] J Virol. 1994 Feb;68(2):1149-57 [7507178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2848-52 [7908445.001]
  • [Cites] J Gen Virol. 1996 Feb;77 ( Pt 2 ):347-58 [8627239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6403-7 [9177230.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):148-53 [9399820.001]
  • [Cites] Am J Hematol. 1998 Feb;57(2):184-5 [9462561.001]
  • [Cites] Virology. 1998 Apr 10;243(2):366-79 [9568035.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1199-203 [9737591.001]
  • [Cites] J Virol Methods. 1998 Nov;75(2):123-40 [9870588.001]
  • [Cites] Br J Haematol. 1999 May;105(2):376-81 [10233407.001]
  • [Cites] Br J Dermatol. 1999 Jul;141(1):44-9 [10417514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Intervirology. 2005;48(6):362-71 [16024940.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Leukemia. 2006 Mar;20(3):451-7 [16424875.001]
  • [Cites] Int J Dermatol. 2006 Apr;45(4):447-9 [16650175.001]
  • [Cites] Cancer Invest. 2001;19(4):383-95 [11405178.001]
  • (PMID = 17284327.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ PMC1802090
  •  go-up   go-down


87. Nishiwaki S, Miyamura K, Kato C, Terakura S, Ohashi K, Sakamaki H, Nakao S, Harigae H, Kodera Y: Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Res; 2010 Jun;30(6):2415-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
  • To evaluate the effect of post-transplant imatinib administration, 34 Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph(+)ALL) patients were retrospectively analysed, with 7 receiving post-transplant imatinib administration.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Child. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Retrospective Studies. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651401.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


88. Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ: Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol; 2008 Apr 10;26(11):1843-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
  • PURPOSE: Retrospective studies have shown that adolescents and young adults with acute lymphoblastic leukemia (ALL) treated with pediatric protocols have better outcomes than similarly aged patients treated with adult protocols, but prospective studies comparing adolescents and young adults using pediatric schedules are scarce.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Asparaginase / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Hydrocortisone / administration & dosage. Infant. Infection / chemically induced. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Prognosis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398150.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


89. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S: Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer; 2009 May 15;115(10):2147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
  • BACKGROUND: Among the well described cytogenetic abnormalities in adults with acute lymphoblastic leukemia (ALL), a translocation involving chromosomes 1 and 19 (t[1;19] [q23;p13]) occurs in a small subset but has been associated variously with an intermediate prognosis or a bad prognosis in different studies.
  • Patients with t(1;19) had significantly better CRD and OS compared with all other patients combined and compared individually with patients who had Philadelphia chromosome-positive, t(4;11), and lymphoma-like abnormalities (deletion 6q, addition q14q, t[11;14], and t[14;18]).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Cytarabine / administration & dosage. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Humans. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4920-9 [10490826.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2155-61 [17039234.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Blood. 1986 Feb;67(2):415-20 [3455828.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2276-85 [11187919.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):484-7 [12580965.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Blood. 1984 Mar;63(3):721-4 [6607758.001]
  • [Cites] Blood. 1987 Oct;70(4):948-53 [3307953.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):994-1004 [2189958.001]
  • [Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]
  • [Cites] Leukemia. 1992 May;6(5):363-9 [1593901.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2601-6 [7989935.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1985-9 [8609706.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1211-24 [8608207.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4252-8 [8943861.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;220:25-43 [9103673.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):527-35 [9469337.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):35-42 [10334640.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • (PMID = 19298009.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; CVAD protocol
  • [Other-IDs] NLM/ NIHMS629437; NLM/ PMC4199455
  •  go-up   go-down


90. Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer A, Schuh A, Yee K, Messner HA: Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer; 2008 Apr 1;112(7):1513-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / etiology. Neoplasms / therapy. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Phenotype. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


91. Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodríguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R, Gonzalez-Carrillo ML, Ruiz-Argüelles GJ: Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant; 2007 Sep;40(6):535-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study.
  • Using non-myeloablative conditioning, allogeneic hematopoietic stem cell transplantation (HSCT) was conducted in 43 ALL patients in a CR2.
  • These results are inferior to those obtained using the same allografting method in other leukemias, probably as a consequence of poor susceptibility to the graft-versus-leukemia effect of the ALL cells beyond first remission as compared with other hematological malignancies.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Granulocytes / cytology. Humans. Infant. Leukocyte Count. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Survival Rate. Transplantation, Homologous


92. Yoshimitsu M, Fujiwara H, Ozaki A, Hamada H, Matsushita K, Arima N, Tei C: Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. Int J Hematol; 2008 Oct;88(3):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
  • A 23-year-old man with Philadelphia-chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his HLA-identical brother in first hematological remission following induction chemotherapy which included imatinib.
  • Following discontinuation of cyclosporine A, imatinib (600 mg daily) was restarted and 4 days later donor lymphocyte infusion (DLI) (5 x 10(7)/kg of CD3(+) cells) was given.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Living Donors. Lymphocyte Transfusion. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Cyclosporine / administration & dosage. Humans. Imatinib Mesylate. Male. Remission Induction. Siblings. Transplantation, Homologous


93. Whitworth KW, Symanski E, Coker AL: Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995-2004. Environ Health Perspect; 2008 Nov;116(11):1576-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We detected no associations between benzene or 1,3-butadiene levels and lymphoma incidence.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Air Waste Manag Assoc. 2000 Feb;50(2):175-80 [10680346.001]
  • [Cites] Occup Environ Med. 1999 Nov;56(11):774-80 [10658564.001]
  • [Cites] J Am Stat Assoc. 1995 Mar;90(429):64-71 [12155398.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):665-73 [12296514.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):386-91 [12843760.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):596-9 [14696126.001]
  • [Cites] Environ Health Perspect. 2004 Feb;112(2):257-65 [14754581.001]
  • [Cites] Occup Environ Med. 2004 Sep;61(9):773-8 [15317919.001]
  • [Cites] Environ Health Perspect. 2004 Oct;112(14):1386-92 [15471730.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1982 May;29:1-398 [6957379.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:105-10 [8549455.001]
  • [Cites] J Epidemiol Community Health. 1995 Dec;49 Suppl 2:S20-7 [8594128.001]
  • [Cites] Milbank Q. 1996;74(2):215-38 [8632735.001]
  • [Cites] Int Arch Occup Environ Health. 1997;70(1):57-60 [9258708.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1999;71 Pt 1:1-315 [10507919.001]
  • [Cites] Science. 2004 Dec 3;306(5702):1774-6 [15576619.001]
  • [Cites] J Epidemiol Community Health. 2005 Feb;59(2):101-5 [15650139.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] J Epidemiol Community Health. 2005 Sep;59(9):755-60 [16100313.001]
  • [Cites] Mutat Res. 2006 Jan;612(1):14-39 [16027031.001]
  • [Cites] J Epidemiol Community Health. 2006 Feb;60(2):136-41 [16415262.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2920-9 [16425269.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2006 Nov;16(6):538-43 [16736057.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):138-45 [17366834.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1388-93 [17938725.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2008 Jan;18(1):45-58 [17878926.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:13-8 [8549460.001]
  • [Cites] Am J Epidemiol. 2001 Mar 1;153(5):433-43 [11226975.001]
  • (PMID = 19057714.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128106; United States / NCI NIH HHS / CA / 1 R03 CA128106-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants
  • [Other-IDs] NLM/ PMC2592281
  • [Keywords] NOTNLM ; 1,3-butadiene / air toxics / benzene / childhood cancer / epidemiology / hazardous air pollution
  •  go-up   go-down


94. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW, Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute: Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood; 2007 Apr 15;109(8):3189-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
  • However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities.
  • We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
  • [MeSH-major] Chromosome Deletion. Philadelphia Chromosome. Ploidies. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Karyotyping. Leukocyte Count. Multivariate Analysis. Risk Factors. Survival Rate. Treatment Failure


95. Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T, EORTC Leukemia Group: Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica; 2010 Sep;95(9):1489-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
  • BACKGROUND: Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • DESIGN AND METHODS: Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were randomized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone 8 mg/m(2) or prednisolone 60 mg/m(2).
  • CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):767-74 [7889010.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):1-12 [7743230.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2007 Apr;21(4):593-4 [17301807.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):267-73 [17961726.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:103 [19036151.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):984-91 [19621425.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2193-4 [11187910.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Apr-May;18(3):187-91 [11293286.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • (PMID = 20378563.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / CA11488-25; United States / NCI NIH HHS / CA / CA11489-39
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2930949
  •  go-up   go-down


96. Kuhle S, Spavor M, Massicotte P, Halton J, Cherrick I, Dix D, Mahoney D, Bauman M, Desai S, Mitchell LG: Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost; 2008 Apr;6(4):589-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia.
  • BACKGROUND: Deep vein thrombosis (DVT) is a complication of treatment of acute lymphoblastic leukemia (ALL) in children but little is known about the long-term outcomes of these DVT.
  • Group II consisted of non-selected childhood ALL survivors <21 years.
  • [MeSH-major] Postthrombotic Syndrome / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Venous Thrombosis / complications
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antithrombin III Deficiency / chemically induced. Arm / blood supply. Arm / pathology. Asparaginase / administration & dosage. Asparaginase / adverse effects. Catheterization, Central Venous / adverse effects. Child. Child, Preschool. Clinical Trials, Phase II as Topic / statistics & numerical data. Collateral Circulation. Cross-Sectional Studies. Female. Follow-Up Studies. Humans. Incidence. Male. Multicenter Studies as Topic / statistics & numerical data. Prevalence. Randomized Controlled Trials as Topic / statistics & numerical data. Survivors. Thrombophilia / chemically induced

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194413.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


97. Mukherjee K, Chava AK, Bandyopadhyay S, Mallick A, Chandra S, Mandal C: Co-expression of 9-O-acetylated sialoglycoproteins and their binding proteins on lymphoblasts of childhood acute lymphoblastic leukemia: an anti-apoptotic role. Biol Chem; 2009 Apr;390(4):325-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of 9-O-acetylated sialoglycoproteins and their binding proteins on lymphoblasts of childhood acute lymphoblastic leukemia: an anti-apoptotic role.
  • Enhanced levels of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)GPs) as disease-associated molecules was reported to act as signaling molecules for promoting survival of lymphoblasts in childhood acute lymphoblastic leukemia (ALL).
  • Accordingly, we examined the presence of binding proteins for Neu5,9Ac(2)GPs on cell lines and primary cells of patients with B- and T-ALL, at presentation of the disease.
  • Peripheral blood mononuclear cells from normal healthy donors and cells from myeloid leukemia patients were used for comparison.
  • This is the first report of the presence of potential physiological ligands for disease-associated molecules like Neu5,9Ac(2)GPs, the interaction of which is able to trigger an anti-apoptotic signal conferring a survival advantage to leukemic cells in childhood ALL.
  • [MeSH-major] Apoptosis. Lymphocytes / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Sialoglycoproteins / metabolism
  • [MeSH-minor] Acetylation. Adolescent. Adult. Blotting, Western. Cell Cycle / drug effects. Cell Line. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Male. Microscopy, Confocal. Middle Aged. Protein Binding. Young Adult


98. Reichard KK, Zhang QY, Sanchez L, Hozier J, Viswanatha D, Foucar K: Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: case report and review of the literature. Am J Hematol; 2006 Mar;81(3):178-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: case report and review of the literature.
  • We report a case of donor-derived acute myeloid leukemia (AML) occurring in a 33-year-old man after allogeneic bone marrow transplantation (BMT) for precursor T-cell acute lymphoblastic -leukemia (T-ALL).
  • The cells for BMT were from his human leukocyte antigen (HLA)-matched sister.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myeloid, Acute / etiology. Living Donors. Neoplasms, Second Primary / etiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Chimera
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Human / genetics. Female. Humans. In Situ Hybridization, Fluorescence / methods. Karyotyping. Male. Transplantation, Homologous


99. Pan J, Xue Y, Wu Y, Wang Y, Shen J: Dicentric (7;9)(p11;p11) is a rare but recurrent abnormality in acute lymphoblastic leukemia: a study of 7 cases. Cancer Genet Cytogenet; 2006 Sep;169(2):159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dicentric (7;9)(p11;p11) is a rare but recurrent abnormality in acute lymphoblastic leukemia: a study of 7 cases.
  • A clinical and experimental study of acute lymphoblastic leukemia (ALL) with a dic(7;9)(p11;p11) included 7 patients (5 males and 2 females) with a median age of 32 years.
  • Cytogenetic analysis of bone marrow cells using an R-band technique showed a solitary dic(7;9) in 2 cases and a dic(7;9) accompanied by other abnormalities in 5 cases, of which 4 had also a t(9;22)(q34;q11).
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 9. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Centromere. Child. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938575.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Koenigsmann M, Koehler K, Regner A, Franke A, Frommer J: Facing mortality: a qualitative in-depth interview study on illness perception, lay theories and coping strategies of adult patients with acute leukemia 1 week after diagnosis. Leuk Res; 2006 Sep;30(9):1127-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facing mortality: a qualitative in-depth interview study on illness perception, lay theories and coping strategies of adult patients with acute leukemia 1 week after diagnosis.
  • [MeSH-major] Adaptation, Psychological. Interviews as Topic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Stress, Psychological
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Patient Education as Topic

  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458356.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement